Epigenome-wide analysis reveals potential biomarkers for radiation-induced toxicity risk in prostate cancer.

ABSTRACT:

Background

Prostate cancer is the second most common cancer globally, with radiation therapy (RT) being a key treatment for clinically localized and locally advanced cases. Given high survival rates, addressing long-term side effects of RT is crucial for preserving quality-of-life. Radiogenomics, the study of genetic variations affecting response to radiation, has primarily focussed on genomic biomarkers, while DNA methylation studies offer insights into RT responses. Although most research has centred on tumours, no epigenome-wide association studies have explored peripheral blood biomarkers of RT-induced toxicities in prostate cancer patients. Identifying such biomarkers could reveal molecular mechanisms underlying RT response and enable personalized treatment.

Methods

We

SUBMITTER: Lopez-Pleguezuelos C 

PROVIDER: S-EPMC11887099 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature